No mRNA Me-Too? CureVac Spies 2021 Launch For COVID-19 Vaccine
EU Backing Gives Company Options
Executive Summary
Pfizer and Moderna have set a high bar, but CureVac's mRNA contender is buoyed by a big EU procurement deal and a favorable stability profile as it heads into pivotal trials.
You may also be interested in...
CureVac Launches IPO, Adds To Big 2020 Cash Haul
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.